Veblen on the Crossroad: Global Pharmaceuticals and Financialization of Vaccine Production in the Pandemic Period

dc.contributor.authorDoruk, Omer Tugsal
dc.date.accessioned2025-01-06T17:43:22Z
dc.date.available2025-01-06T17:43:22Z
dc.date.issued2024
dc.description.abstractIn the present study, I explore the link between COVID-19 vaccine patents and their financialization within the institutional economics framework. Thorstein Veblen's main assumptions related to financialization of intangible assets are valid for the pharmaceutical firms that produced COVID-19 vaccines during the pandemic. In this context, the effects of patent applications on the financialization of pharmaceutical firms are investigated for companies that took government grants for vaccine production. These firms are examined in a comparative way in the present study. The market figures, the investigation of the relevant firm-level data, and the institutional setting suggest that the COVID-19 vaccine patents-financialization nexus is well defined in the Veblenian framework during the pandemic.
dc.identifier.doi10.1080/00213624.2024.2382026
dc.identifier.endpage839
dc.identifier.issn0021-3624
dc.identifier.issn1946-326X
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85203687974
dc.identifier.scopusqualityQ3
dc.identifier.startpage825
dc.identifier.urihttps://doi.org/10.1080/00213624.2024.2382026
dc.identifier.urihttps://hdl.handle.net/20.500.14669/2644
dc.identifier.volume58
dc.identifier.wosWOS:001306309500004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherRoutledge Journals, Taylor & Francis Ltd
dc.relation.ispartofJournal of Economic Issues
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241211
dc.subjectintangible assets
dc.subjectfinancialization
dc.subjectpharmaceutical firms
dc.subjectCOVID-19 pandemic
dc.subjectInstitutional economics
dc.subjectB5
dc.subjectL25
dc.subjectO34
dc.titleVeblen on the Crossroad: Global Pharmaceuticals and Financialization of Vaccine Production in the Pandemic Period
dc.typeArticle

Dosyalar